Low-Level Viremia Persists for at Least 7 Years in Patients on Suppressive Antiretroviral Therapy von Palmer, Sarah, Maldarelli, Frank, Wiegand, Ann, Bernstein, Barry, Hanna, George J., Brun, Scott C., Kempf, Dale J., Mellors, John W., Coffin, John M., King, Martin S.

Volltext

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia von Maldarelli, Frank, Palmer, Sarah, King, Martin S, Wiegand, Ann, Polis, Michael A, Mican, JoAnn, Kovacs, Joseph A, Davey, Richard T, Rock-Kress, Diane, Dewar, Robin, Liu, Shuying, Metcalf, Julia A, Rehm, Catherine, Brun, Scott C, Hanna, George J, Kempf, Dale J, Coffin, John M, Mellors, John W

Volltext

A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy von Cameron, D. William, da Silva, Barbara A., Arribas, Jose R., Myers, Robert A., Bellos, Nicholaos C., Gilmore, Norbert, King, Martin S., Bernstein, Barry M., Brun, Scott C., Hanna, George J.

Volltext

Relationship between Adherence and the Development of Resistance in Antiretroviral-Naive, HIV-1—Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir von King, Martin S., Brun, Scott C., Kempf, Dale J.

Volltext

Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected P... von Benson, Constance A., Deeks, Steven G., Brun, Scott C., Gulick, Roy M., Eron, Joseph J., Kessler, Harold A., Murphy, Robert L., Hicks, Charles, King, Martin, Wheeler, David, Feinberg, Judith, Stryker, Richard, Sax, Paul E., Riddler, Sharon, Thompson, Melanie, Real, Kathryn, Hsu, Ann, Kempf, Dale, Japour, Anthony J., Sun, Eugene

Volltext

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food eff... von ENDERS KLEIN, Cheri, CHIU, Yi-Lin, AWNI, Walid, TONG ZHU, HEUSER, Renee S, DOAN, Thao, BREITENBACH, Joerg, MORRIS, John B, BRUN, Scott C, HANNA, George J

Volltext

Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy—Naive Patients von King, Martin S., Bernstein, Barry M., Walmsley, Sharon L., Sherer, Renslow, Feinberg, Judith, Sanne, Ian, Cernohous, Paul, Montaner, Julio S. G., Brun, Scott, Sun, Eugene

Volltext

A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen von Johnson, Margaret A, Gathe, Joseph C, Podzamczer, Daniel, Molina, Jean-Michel, Naylor, Christian T, Chiu, Yi-Lin, King, Martin S, Podsadecki, Thomas J, Hanna, George J, Brun, Scott C

Volltext

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates fro... von Kempf, D J, Isaacson, J D, King, M S, Brun, S C, Xu, Y, Real, K, Bernstein, B M, Japour, A J, Sun, E, Rode, R A

Volltext

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study von Hicks, Charles, King, Martin S, Gulick, Roy M, White, Jr, A Clinton, Eron, Jr, Joseph J, Kessler, Harold A, Benson, Constance, King, Kathryn R, Murphy, Robert L, Brun, Scott C

Volltext

Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy von Yang, Aiming, King, Martin S, Han, Lixin, Isaacson, Jeffrey D, Mueller, Toby, Grimm, David R, Scott, C Brun, Katz, David A

Volltext

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir t... von KEMPF, Dale J, ISAACSON, Jeffrey D, KING, Martin S, BRUN, Scott C, SYLTE, Jacquelyn, RICHARDS, Bruce, BERNSTEIN, Barry, RODE, Richard, SUN, Eugene

Volltext

Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus-Coinfected Subjects With Hepatic Impairment von Peng, Joanna Z., Pulido, Federico, Causemaker, Sonja J. Kemmis, Li, Jianling, Lorenzo, Alicia, Cepeda, Concepción, Cabanillas, Juan A. García, DaSilva, Barbara, Brun, Scott C., Arribas, José

Volltext

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment von Haubrich, Richard H, Riddler, Sharon A, DiRienzo, A Gregory, Komarow, Lauren, Powderly, William G, Klingman, Karin, Garren, Kevin W, Butcher, David L, Rooney, James F, Haas, David W, Mellors, John W, Havlir, Diane V

Volltext

Hepatitis C pharmacogenetics: State of the art in 2010 von Afdhal, Nezam H., McHutchison, John G., Zeuzem, Stefan, Mangia, Alessandra, Pawlotsky, Jean‐Michel, Murray, Jeffrey S., Shianna, Kevin V., Tanaka, Yasuhito, Thomas, David L., Booth, David R., Goldstein, David B.

Volltext

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy von Palmer, Sarah, Maldarelli, Frank, Wiegand, Ann, Bernstein, Barry, Hanna, George J, Brun, Scott C, Kempf, Dale J, Mellors, John W, Coffin, John M, King, Martin S

Volltext

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected von Benson, Constance A, Deeks, Steven G, Brun, Scott C, Gulick, Roy M

Volltext

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. Commentary von HICKS, Charles, KING, Martin S, KATZENSTEIN, David, GULICK, Roy M, WHITE, A. Clinton, ERON, Joseph J, KESSLER, Harold A, BENSON, Constance, KING, Kathryn R, MURPHY, Robert L, BRUN, Scott C

Volltext

Kaposi's sarcoma of the ocular adnexa von Brun, S C, Jakobiec, F A

Volltext

Autonomous transportation technology von OLIVER CHRISTOPHER, BRUN SCOTT C, SCHWARTZ JUSTIN MICHAEL

Volltext bestellen